


## CL075

<b>Cat. No.:</b>	HY-117066		
<b>CAS No.:</b>	256922-53-9		
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>13</sub> N <sub>3</sub> S		
<b>Molecular Weight:</b>	243.33		
<b>Target:</b>	Toll-like Receptor (TLR)		
<b>Pathway:</b>	Immunology/Inflammation		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 22 mg/mL (90.41 mM; Need ultrasonic and warming)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	4.1096 mL	20.5482 mL	41.0965 mL
	5 mM	0.8219 mL	4.1096 mL	8.2193 mL
	10 mM	0.4110 mL	2.0548 mL	4.1096 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively<sup>[1][2][3]</sup>.

#### IC<sub>50</sub> & Target

TLR8

#### In Vitro

CL075 (2 μM; 4 h) induces the production of IL-6, IL-8, and IFN-γ in rabbit splenocytes<sup>[1]</sup>.  
 CL075 (2 μM; 48 h) induces the total IgM production and cell proliferation in rabbit splenocytes<sup>[1]</sup>.  
 CL075 (2 μM; 7 h) activates the rabTLR8 in 293 cells<sup>[1]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

CL075 (5 μM (0.5 mL); s.c.) activates a mild antigen-specific antibody response in rabbits<sup>[1]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- Burns. 2023 Jun 16.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

- [1]. Lai CY, et, al. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7. *Vaccine*. 2014 Sep 29;32(43):5593-9.
- [2]. Spranger S, et, al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. *J Immunol*. 2010 Jul 1;185(1):738-47.
- [3]. Maalej KM, et, al. TLR8, but not TLR7, induces the priming of the NADPH oxidase activation in human neutrophils. *J Leukoc Biol*. 2015 Jun;97(6):1081-7.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA